Immunogenicity and toxicokinetics assessment of the mono-PEGylated recombinant human interleukin-11 in cynomolgus monkeys.

[1]  Q. Choo,et al.  Pharmacokinetic and Pharmacodynamic Evaluation of Different PEGylated Human Interleukin-11 Preparations in Animal Models. , 2018, Journal of pharmaceutical sciences.

[2]  Qin Xu,et al.  Preclinical evaluation of the mono‐PEGylated recombinant human interleukin‐11 in cynomolgus monkeys , 2018, Toxicology and applied pharmacology.

[3]  Q. Choo,et al.  Efficient expression and isolation of recombinant human interleukin-11 (rhIL-11) in Pichia pastoris. , 2018, Protein expression and purification.

[4]  Guang-Rong Zhao,et al.  The pharmacokinetic and pharmacodynamic properties of site‐specific pegylated genetically modified recombinant human interleukin‐11 in normal and thrombocytopenic monkeys , 2017, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[5]  Ivana Knezevic,et al.  Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility. , 2015, Biologicals : journal of the International Association of Biological Standardization.

[6]  Yang Zhang,et al.  Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy , 2012, Supportive Care in Cancer.

[7]  Steven J Swanson,et al.  Immunogenicity assessment in non-clinical studies. , 2012, Current opinion in microbiology.

[8]  B. Meibohm,et al.  Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy , 2012, The AAPS Journal.

[9]  Jong‐Mook Kim,et al.  Improvement of biological and pharmacokinetic features of human interleukin-11 by site-directed mutagenesis. , 2011, Biochemical and biophysical research communications.

[10]  Rafael Ponce,et al.  Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. , 2009, Regulatory toxicology and pharmacology : RTP.

[11]  M. Hashida,et al.  Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[12]  M. Cotreau,et al.  A multiple‐dose, safety, tolerability, pharmacokinetics and pharmacodynamic study of oral recombinant human interleukin‐11 (oprelvekin) , 2004, Biopharmaceutics & drug disposition.

[13]  C. Begley,et al.  Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. , 2002, Blood.

[14]  W. Trepicchio,et al.  Hematopoietic, immunomodulatory and epithelial effects of interleukin-11 , 1999, Leukemia.

[15]  J. Vredenburgh,et al.  A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[16]  D. Williams,et al.  Interleukin-11: review of molecular, cell biology, and clinical use. , 1997, Blood.

[17]  W. McCaskill-Stevens,et al.  A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. , 1996, Blood.

[18]  H. Tanaka,et al.  Pharmacokinetics of recombinant human granulocyte colony-stimulating factor studied in the rat by a sandwich enzyme-linked immunosorbent assay. , 1990, The Journal of pharmacology and experimental therapeutics.

[19]  M. Hashida,et al.  Renal Disposition of Recombinant Human Interleukin-11 in the Isolated Perfused Rat Kidney , 2004, Pharmaceutical Research.

[20]  H. Mizoguchi,et al.  Effect of interleukin 11 on normal and pathological thrombopoiesis , 1996, Cancer Chemotherapy and Pharmacology.

[21]  M. Gordon.  Thrombopoietic activity of recombinant human interleukin 11 in cancer patients receiving chemotherapy , 1996, Cancer Chemotherapy and Pharmacology.